Close Menu

NEW YORK – The US Food and Drug Administration announced Tuesday that it has authorized Vela Diagnostics' next-generation sequencing-based HIV-1 drug resistance mutation assay for marketing through its de novo premarket review pathway.

The agency said the test — called the Sentosa SQ HIV Genotyping Assay — is the first HIV drug resistance assay utilizing NGS technology that the FDA has authorized for marketing in the US.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A new blood test might be able to detect the presence of some 50 cancers, according to New Scientist.

Undark looks into how coronavirus-related shutdowns are affecting field researchers.

In PNAS this week: strategies to design DNA oligonucleotide probes for bacteria, Vibrio cholerae evolution in Haiti, and more.

NPR reports that graduate students in the US are helping with SARS-CoV-2 testing.

May
06
Sponsored by
Isoplexis

This webinar will discuss the application of single-cell proteomics and immune-imaging in adoptive cell therapy (ACT) for cancer.